Last reviewed · How we verify
ETHIODIZED OIL
At a glance
| Generic name | ETHIODIZED OIL |
|---|---|
| Drug class | Radiographic Contrast Agent [EPC] |
| Phase | FDA-approved |
| First approval | 1954 |
Approved indications
Boxed warnings
- WARNING: FOR INTRALYMPHATIC, INTRAUTERINE AND SELECTIVE HEPATIC INTRA-ARTERIAL USE ONLY Pulmonary and cerebral embolism can result from inadvertent intravascular injection or intravasation of Lipiodol. Inject Lipiodol slowly with radiologic monitoring; do not exceed recommended dose ( 5.1 ). WARNING: FOR INTRALYMPHATIC, INTRAUTERINE AND SELECTIVE HEPATIC INTRA-ARTERIAL USE ONLY See Full Prescribing Information for complete Boxed Warning Pulmonary and cerebral embolism can result from inadvertent intravascular injection or intravasation of Lipiodol. Inject Lipiodol slowly with radiologic monitoring; do not exceed recommended dose ( 5.1 ).
Common side effects
- Abdominal pain
- Nausea
- Vomiting
- Fever
- Pain
- Dyspnea
- Cough
- Headache
- Skin rash
- Allergic dermatitis
- Edema
- Soreness of mouth and pharynx
Serious adverse events
- Pulmonary embolism
- Cerebral embolism
- Hypersensitivity reactions
- Anaphylactic reaction
- Acute respiratory distress syndrome
- Hepatic vein thrombosis
- Retinal vein thrombosis
- Liver decompensation
- Exacerbation of chronic liver disease
- Thyroid dysfunction
Drug interactions
- Radioactive Iodine (I-131)
- Thyroid Function Tests
Key clinical trials
- Prevention of Variceal Rebleeding by EUS-guided vs Conventional Endoscopic Therapy in Hepatocellular Carcinoma Patients (NA)
- Selective Internal Radiation Therapy and 188Re-SSS Lipiodol Treatment for Liver Cancer (Lip-Re2) (PHASE2)
- Safety and Efficacy of LVD + C-TACE + Tis/Len for Unresectable Right-Liver HCC (NA)
- Achilles Tendinopathy Embolization (PHASE1)
- Phase II Trial of Lung Chemoemobolization (PHASE2)
- MANDARIN (S6371) (PHASE3)
- CECT Features of MVI Predict Response to TACE Plus TKI in Intermediate-stage HCC
- Adjuvant TACE in HCC With High-risk Recurrence Factors (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |